Efficacy outcomes within 90 days
| Tenecteplase | Alteplase | Effect size (95% CI) | P value | |
| Primary outcome | ||||
| mRS score 0–1 at 90 days (n=134) | 37/75 (49.3%) | 20/59 (33.9%) | – | – |
| Risk ratio | – | – | 1.47 (0.96 to 2.23) | – |
| OR | – | – | 1.90 (0.94 to 3.84) | – |
| Difference in proportion | – | – | 0.16 (-0.01 to 0.33) | – |
| Primary outcome (per-protocol) | ||||
| mRS score 0–1 at 90 days (n=130) | 37/73 (50.7%) | 19/57 (33.3%) | – | – |
| Risk ratio | – | – | 1.50 (0.98 to 2.29) | – |
| OR | – | – | 2.06 (1.00 to 4.21) | – |
| Difference in proportion | – | – | 0.17 (-0.002 to 0.35) | – |
| Secondary outcomes (modified intention-to-treat) | ||||
| mRS score 0–2 at 90 days (n=134) | 46/75 (61.3%) | 26/59 (44.1%) | 2.01 (1.01 to 4.03) | 0.048 |
| mRS at 3 months (n=134) | 2 (0 to 4) | 3 (1 to 5) | 1.90 (1.04 to 3.50) | 0.04 |
| Major neurological improvement at 24 hours (n=134) | 38/74 (51.4%) | 21/60 (35.0%) | 1.96 (0.97 to 3.95) | 0.06 |
| Major neurological improvement at 7 days or discharge (n=122) | 49/68 (72.1%) | 33/54 (61.1%) | 1.64 (0.77 to 3.52) | 0.20 |
| European quality of life visual analogue scale (n=110) | 80.0 (60.0 to 90.0) | 80.0 (60.0 to 90.0) | −3.38 (-12.11 to 5.36) | 0.44 |
| Barthel Index≥95 (n=111) | 36/64 (56.3%) | 17/47 (36.2) | 2.27 (1.05 to 4.92) | 0.04 |
mRS, modified Rankin Scale.